Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | NPC1 | O15118 | 3/20 | 0.81 |
| ▸ | RAB9A | P51151 | 3/20 | 0.81 |
| ▸ | GLA | P06280 | 1/20 | 0.81 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.81 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.81 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.81 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.81 |
| ▸ | CBFB | Q13951 | 1/20 | 0.81 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125080 | 1.00 | KDM4E (0.81) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL18075701 | 0.90 | KDM4E (1.00) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL28647309 | 0.86 | MEN1 (0.60) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL4157750 | 0.85 | KDM4E (0.58) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL24527524 | 0.85 | MAPT (0.58) | KDM4EMEN1KMT2AMAPTNPC1 | |
| Proflavine SCHEMBL28425236 | 0.81 | KMT2A (0.72) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL24527534 | 0.81 | MEN1 (0.53) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL24527544 | 0.81 | TERT (0.60) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL24527584 | 0.80 | MEN1 (0.52) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL7168746 | 0.79 | MEN1 (0.58) | KDM4EMEN1KMT2AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250290918-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2025-09-18 | — | — | US | claimed |
| US-11796534-B2 | Methods for assessing cell surface glycosylation | JUNO THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-114324625-A | Oligosaccharide marker and application thereof in cubilose identification | 香港名贵中药检定中心有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20250306030-A1 | METHODS FOR MASS SPECTROMETRY ANALYSIS OF ENGINEERED CELL COMPOSITIONS | JUNO THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250290918-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-12379375-B2 | Methods for assessing cell surface glycosylation | JUNO THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12366580-B2 | Methods for mass spectrometry analysis of engineered cell compositions | JUNO THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-113383003-B | Method, kit and device for preparing sugar chain from glycoprotein | 国立研究开发法人产业技术综合研究所 | 2024-11-08 | — | — | CN | disclosed |
| EP-4421168-A2 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-3960854-B1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | HALOZYME INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118326524-A | Improved sugar chain library preparation method | 北京普利米特生物科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4269578-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11796534-B2 | Methods for assessing cell surface glycosylation | JUNO THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116391043-A | Method for producing protein | 百时美施贵宝公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11491212-B1 | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B | CATALYST BIOSCIENCES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-115261425-A | Method, kit and apparatus for producing sugar chain of glycoprotein | 住友电木株式会社 | 2022-11-01 | — | — | CN | disclosed |
| CN-114981659-A | Method for quantifying unmarked N-glycans | 百时美施贵宝公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114324625-A | Oligosaccharide marker and application thereof in cubilose identification | 香港名贵中药检定中心有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3960854-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20220050114-A1 | METHODS FOR MASS SPECTROMETRY ANALYSIS OF ENGINEERED CELL COMPOSITIONS | JUNO THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491212-B1 | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B | F13B, F13A1, F9 | KDM4E 2231/4885MEN1 2451/4885KMT2A 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.